Table 3

Effect modification between patients with SLE and hospital-based controls

Patients with SLEControlsCox proportional hazards
DiedPerson-yearsDiedPerson-yearsaHR (95% CI) *
Prevalent thromboembolic events95239318042891.32 (1.02 to 1.71)
No prevalent thromboembolic disease45323 3182270276 3472.13 (1.92 to 2.37)
History of harmful alcohol use3369812744131.29 (0.88 to 1.91)
No history of harmful alcohol use51525 0132323276 2242.06 (1.86 to 2.27)
History of smoking131380849620 3091.69 (1.38 to 2.07)
No history of smoking41721 9021954260 3282.09 (1.88 to 2.33)
History of obesity63127711855011.97 (1.41 to 2.76)
No history of obesity48524 4332332275 1362.03 (1.84 to 2.25)
Prevalent hypertension194383671314 9021.47 (1.24 to 1.74)
Normotensive35421 8741737265 7352.25 (2.00 to 2.54)
Prevalent hypothyroidism4010166720411.47 (0.98 to 2.22)
Normal thyroid function50824 6942383278 5962.05 (1.86 to 2.26)
Prevalent dyslipidaemia4557719143101.58 (1.13 to 2.22)
Normal lipid levels50325 1342259276 3262.06 (1.86 to 2.27)
Prevalent diabetes6899535564671.26 (0.96 to 1.65)
Non-diabetic48024 7152095274 1702.17 (1.95 to 2.40)
IV/IM corticosteroids ever7134203026481.78 (1.13 to 2.78)
No IV/IM corticosteroids ever47722 2902420277 9881.98 (1.79 to 2.19)
  • Bolded HRs were statistically significant, p<0.05.

  • *Adjusted for age, sex, Aboriginality and Charlson Comorbidity Index categories. Interaction testing, all p>0.20.